
The U.S. Food and Drug Administration approves first biologic for treatment of eczema
13/04/2017
On March 28th 2017, the US Food and Drug Administration (FDA) approved a new drug called dupilumab (brand name: Dupixent) for the treatment of adults with moderate-to-severe atopic dermatitis (also known as atopic eczema) that is not adequately controlled with topical treatment, or for whom topical treatments are not appropriate This new drug is administered by injection under the skin and can...
Read more